tradingkey.logo

AstraZeneca PLC

AZN
View Detailed Chart

68.460USD

-5.460-7.38%
Close 04/04, 16:00ETQuotes delayed by 15 min
212.30BMarket Cap
30.18P/E TTM

AstraZeneca PLC

68.460

-5.460-7.38%
Intraday
1m
30m
1h
D
W
M
D

Today

-7.38%

5 Days

-7.21%

1 Month

-11.63%

6 Months

-11.63%

Year to Date

+4.48%

1 Year

+1.49%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 12 analysts
BUY
Current Rating
86.743
Target Price
26.71%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

150
Total
5
Median
7
Average
Company name
Ratings
Analysts
AstraZeneca PLC
AZN
12
Biogen Inc
BIIB
37
Amgen Inc
AMGN
33
Alnylam Pharmaceuticals Inc
ALNY
33
Gilead Sciences Inc
GILD
30
BioMarin Pharmaceutical Inc
BMRN
29
1
2
3
...
30

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(10)
Neutral(2)
Buy(0)
Indicators
Sell(4)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-1.270
Sell
RSI(14)
31.241
Neutral
STOCH(KDJ)(9,3,3)
17.933
Neutral
ATR(14)
1.731
High Vlolatility
CCI(14)
-190.158
Sell
Williams %R
99.615
Oversold
TRIX(12,20)
-0.147
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
72.146
Sell
MA10
72.720
Sell
MA20
74.466
Sell
MA50
73.868
Sell
MA100
70.025
Sell
MA200
74.517
Sell

Company

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Company codeAZN
CompanyAstraZeneca PLC
CEOMr. Marc Dunoyer
Websitehttps://www.astrazeneca.com/
tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.